852045-46-6 Usage
Uses
Used in Pharmaceutical Industry:
FLT3 Inhibitor III is used as a research tool for studying the role of FLT3 in various cellular processes and its involvement in diseases such as acute myeloid leukemia (AML). Its high selectivity and potency make it a valuable compound for investigating the therapeutic potential of FLT3 inhibition in the treatment of FLT3-mutated cancers.
Used in Cancer Research:
FLT3 Inhibitor III is used as a chemical probe to explore the molecular mechanisms underlying FLT3-mediated signaling pathways and their contribution to the development and progression of cancers, particularly AML. It aids in understanding the role of FLT3 mutations, such as FLT3-ITD, in driving oncogenic processes and helps identify potential therapeutic targets for the development of novel anti-cancer agents.
Used in Drug Development:
FLT3 Inhibitor III serves as a lead compound in the development of FLT3-targeted therapies. Its high potency and selectivity make it an attractive starting point for the design and optimization of new drugs aimed at inhibiting FLT3 activity, which could potentially lead to the development of more effective treatments for patients with FLT3-mutated cancers.
Check Digit Verification of cas no
The CAS Registry Mumber 852045-46-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,5,2,0,4 and 5 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 852045-46:
(8*8)+(7*5)+(6*2)+(5*0)+(4*4)+(3*5)+(2*4)+(1*6)=156
156 % 10 = 6
So 852045-46-6 is a valid CAS Registry Number.
852045-46-6Relevant academic research and scientific papers
Aromatic interactions with phenylalanine 691 and cysteine 828: A concept for FMS-like tyrosine kinase-3 inhibition. Application to the discovery of a new class of potential antileukemia agents
Furet, Pascal,Bold, Guido,Meyer, Thomas,Roesel, Johannes,Guagnano, Vito
, p. 4451 - 4454 (2007/10/03)
FLT3 kinase inhibitors are currently under investigation as a new treatment for acute myeloid leukemia. We report here a molecular concept invoking interactions between an aromatic ring and the side chains of Phe691 and Cys828, two residues of the ATP poc
THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS
-
Page/Page column 23-24, (2010/02/11)
The invention relates to thiazole and pyrazole derivatives of formula (I) wherein Q is S and X is C, or Q is CH and X is N; R1 is unsubtituted or substituted phenyl; and R2 is unsubstituted or substituted aryl or heteroaryl; oa a salt of the said compounds, and to processes for the preparation thereof, to pharmaceutical compositions comprising such derivatives and to the use of such derivatives for the preparation of pharmaceutical compositions for the treatment especially of a proliferative disease, such as a tumour disease, in particular such diseases which respond to an inhibition of the FIt-3 kinase.
